Cargando…

Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer

Metabolic reprogramming is a phenomenon in which cancer cells alter their metabolic pathways to support their uncontrolled growth and survival. Platinum-based chemotherapy resistance is associated with changes in glucose metabolism, amino acid metabolism, fatty acid metabolism, and tricarboxylic aci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Jinbowen, Xu, Fangzhi, Zhou, Dan, Zhang, Shuo, Zhang, Bo, Meng, Qingwei, Lv, Qiubo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482409/ https://www.ncbi.nlm.nih.gov/pubmed/37681030 http://dx.doi.org/10.3389/fonc.2023.1231460

Ejemplares similares

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China
por: Zhang, Depu, et al.
Publicado: (2022)

Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer
por: Zhao, Jiangang, et al.
Publicado: (2020)

Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
por: Chien, Jeremy, et al.
Publicado: (2013)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

CD147 Mediates 5-Fluorouracil Resistance in Colorectal Cancer by Reprogramming Glycolipid Metabolism
por: Dong, Shuohui, et al.
Publicado: (2022)

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

Metabolic Reprogramming in Thyroid Carcinoma
por: Coelho, Raquel Guimaraes, et al.
Publicado: (2018)

Characterization of global research trends and prospects on platinum-resistant ovarian cancer: a bibliometric analysis
por: Duan, Yuanqiong, et al.
Publicado: (2023)

Lipid metabolism reprogramming in head and neck cancer
por: Liang, Jinfeng, et al.
Publicado: (2023)

Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism
por: Leung, Dilys, et al.
Publicado: (2022)

Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model
por: Zhang, Yanlong, et al.
Publicado: (2020)

Relationship between metabolic reprogramming and drug resistance in breast cancer
por: Lv, Linlin, et al.
Publicado: (2022)

Biomarking and Induction of Apoptosis in Ovarian Cancer Using Bifunctional Polyethyleneimine-Caged Platinum Nanoclusters
por: Zhang, Mengjun, et al.
Publicado: (2022)

Lymphocyte-to-monocyte ratio after primary surgery is an independent prognostic factor for patients with epithelial ovarian cancer: A propensity score matching analysis
por: Hu, Qian, et al.
Publicado: (2023)

Macrophages and Metabolic Reprograming in the Tumor Microenvironment
por: Liu, Jin, et al.
Publicado: (2022)

Editorial: Metabolic reprogramming in breast cancer
por: Scatena, Cristian, et al.
Publicado: (2022)

Corrigendum: Biomarking and induction of apoptosis in ovarian cancer using bifunctional polyethyleneimine-caged platinum nanoclusters
por: Zhang, Mengjun, et al.
Publicado: (2022)

Deep learning magnetic resonance imaging predicts platinum sensitivity in patients with epithelial ovarian cancer
por: Lei, Ruilin, et al.
Publicado: (2022)

Elucidating the Reprograming of Colorectal Cancer Metabolism Using Genome-Scale Metabolic Modeling
por: Zhang, Cheng, et al.
Publicado: (2019)

Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer
por: Zheng, Hong, et al.
Publicado: (2021)

Gonadotropin-releasing hormone agonist protects ovarian function in young patients with ovarian malignancy undergoing platinum-based chemotherapy: A prospective study
por: Xie, Ya, et al.
Publicado: (2022)

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
por: Li, Yuan, et al.
Publicado: (2021)

Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy
por: Zhang, Leqiang, et al.
Publicado: (2022)

Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy
por: Lin, Jiaxing, et al.
Publicado: (2021)

Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming
por: Adeshakin, Funmilayo O., et al.
Publicado: (2021)

Metabolic Reprogramming During Multidrug Resistance in Leukemias
por: Vidal, Raphael Silveira, et al.
Publicado: (2018)

Editorial: Cell Stress, Metabolic Reprogramming, and Cancer
por: Giannattasio, Sergio, et al.
Publicado: (2018)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Editorial: Hallmark of cancer: Reprogramming of cellular metabolism
por: Kaur, Baljinder, et al.
Publicado: (2023)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Glucose Metabolism Reprogramming of Primary Tumor and the Liver Is Associated With Disease-Free Survival in Patients With Early NSCLC
por: Tan, Hongpei, et al.
Publicado: (2021)

Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia
por: Feng, Lili, et al.
Publicado: (2023)

Knockout of ENO1 leads to metabolism reprogramming and tumor retardation in pancreatic cancer
por: Song, Qingru, et al.
Publicado: (2023)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Predictive Value of HE4 in Platinum-Based Chemotherapy for Ovarian Cancer: A Systematic Review
por: Han, Yue, et al.
Publicado: (2021)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies
por: Xu, Ruiyuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3m0mthp04n7laibkejua0vscas